Review grts


Aime
Gritstone bio (NASDAQ:GRTS) is a small-cap medical company that has received positive analyst recommendations and has shown potential for growth. Here's a detailed review:
- Analyst Recommendations and Price Targets: Gritstone bio has a consensus rating of "Buy" as of September 18, 20241. The average price target for GRTS is $4.332, indicating analysts' expectations for potential upside from the current closing price of $0.633.
1/3
- Financial Performance: Gritstone bio has a negative net margin of 926.13% and a negative return on equity of 232.42%4. The company reported an EPS of ($0.16) for the quarter, which is better than analysts' estimates of ($0.28), showing a surprise of $0.125. This indicates that while the company has been unprofitable, it has managed to exceed analysts' expectations.
- Volatility and Risk: Gritstone bio has a beta of 0.64, suggesting it is less volatile than the S&P 5004. This could be appealing to investors looking for less risk.
- Institutional Ownership and Insider Activity: Institutional ownership stands at 48.5%, and insider ownership is 4.6%4. This shows a significant level of institutional confidence and suggests that insiders have a stake in the company's long-term success.
- Short Interest: Short interest in Gritstone bio decreased by 8.5% in August6, which could be a positive sign as it indicates a decrease in bearish sentiment among short sellers.
- Technical Indicators: The MACD for GRTS is at 0.047, which is a relatively low value and could indicate a potential upward momentum. The RSI is at 83.468, which is close to the overbought territory and suggests that the stock may be overextended.
1/2
GRTS Trend
- Moving Averages: The 5-day moving average is $0.579, and the 10-day moving average is $0.5310, both above the current closing price. This could indicate a short-term downward trend.
GRTS Trend
- Challenges and Outlook: Despite the positive analyst ratings and potential for upside, Gritstone bio faces financial stability issues and has a negative net margin411. The company's business outlook is positive according to 57% of employees12, but there are concerns about layoffs and communication from upper management.
In conclusion, Gritstone bio shows potential for growth based on analyst recommendations and the recent decrease in short interest. However, the company's financial performance raises concerns, and investors should carefully consider the risks involved.
Source:
1.
GRTS Analyst Consensus Rating
more
less
Continue this conversation 

Explore
Screener
Analysis
Learn
News